|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:administeredBy
|
injection
buccal film
sublingual tablet
transdermal patch
|
|
gptkbp:ATCCode
|
N07BC01
|
|
gptkbp:brand
|
gptkb:Belbuca
gptkb:Suboxone
gptkb:Subutex
gptkb:Butrans
|
|
gptkbp:CASNumber
|
52485-79-7
|
|
gptkbp:chemicalClass
|
thebaine derivative
|
|
gptkbp:combines
|
gptkb:naloxone
|
|
gptkbp:contraindication
|
paralytic ileus
severe respiratory depression
acute alcoholism
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:discoveredBy
|
gptkb:Reckitt_&_Colman
|
|
gptkbp:discoveredIn
|
1966
|
|
gptkbp:eliminationHalfLife
|
24-60 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:FDAApproved
|
2002
|
|
gptkbp:hasAddictionPotential
|
yes
|
|
gptkbp:hasMolecularFormula
|
C29H41NO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Buprenorphine
|
|
gptkbp:interactsWith
|
gptkb:benzodiazepines
CYP3A4 inhibitors
other CNS depressants
|
|
gptkbp:KEGGID
|
D00298
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist at kappa-opioid receptor
partial agonist at mu-opioid receptor
|
|
gptkbp:MedlinePlusID
|
a605002
|
|
gptkbp:MeSH_ID
|
D019695
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseTreatment
|
gptkb:naloxone
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:pregnancyRisk
|
may cause neonatal withdrawal
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
644073
DB00921
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
transdermal
intravenous
sublingual
buccal
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
sweating
insomnia
respiratory depression
|
|
gptkbp:UNII
|
33CM23913M
|
|
gptkbp:usedFor
|
pain management
opioid use disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|